Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic nonesmall cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02

被引：13
作者：
Li, B. T. [1 ]
Planchard, D. [2 ]
Goto, K. [3 ]
Smit, E. F. [4 ]
De langen, J. [5 ]
Goto, Y. [6 ]
Ninomiya, K. [7 ]
Kubo, T. [8 ]
Perol, M. [9 ]
Felip, E. [10 ]
Hayashi, H. [11 ]
Nakagawa, K. [11 ]
Shimizu, J. [12 ]
Nagasaka, M. [13 ]
Pereira, K. M. C. [14 ]
Taguchi, A. [15 ]
Ali, A. [16 ]
Karnoub, M.
Yonemochi, R. [14 ]
Janne, P. A. [17 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Med, New York, NY USA
[2] Gustave Roussy, Med Oncol, Villejuif, France
[3] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan
[4] LUMC Leiden Univ, Dept Pulm Dis, Med Ctr, Leiden, Netherlands
[5] Netherlands Canc Inst, Dept Thorac Oncol, Amsterdam, Netherlands
[6] Natl Canc Ctr, Thorac Oncol, Tokyo, Japan
[7] Okayama Univ Hosp, Ctr Comprehens Genom Med, Okayama, Japan
[8] Okayama Univ Hosp, Ctr Clin Oncol, Okayama, Japan
[9] Leon Berard Canc Ctr, Med Oncol, Lyon, France
[10] Vall dHebron Univ Hosp, Med Oncol, Barcelona, Spain
[11] Kindai Univ Hosp, Dept Med Oncol, Osakasayama, Japan
[12] Aichi Canc Ctr Hosp, Thorac Oncol, Nagoya, Aichi, Japan
[13] Univ Calif Irvine, Med, Sch Med, Orange, CA USA
[14] Daiichi Sankyo Inc, Oncol, Basking Ridge, NJ USA
[15] Daiichi Sankyo Co Ltd, Clin Dev, Chuo Ku, Tokyo, Japan
[16] Dauchi Sankyo Europe GmbH, Global Oncol Med Affairs, Munich, Germany
[17] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2354
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1321MO
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing biliary tract cancer (BTC) and pancreatic cancer (PC): Outcomes from DESTINY-PanTumor02 (DP-02)
    Oh, Do-Youn
    Lugowska, Iwona A.
    Stroyakovskiy, Daniil
    Jung, Kyung Hae
    Dumas, Olivier
    Penkov, Konstantin
    Dechaphunkul, Arunee
    Oaknin, Ana
    Kim, Seung Tae
    Starling, Naureen
    Chewaskulyong, Busyamas
    Charonpongsuntorn, Chanchai
    Doroshow, Deborah Blythe
    Hsiao, Sheng-Yen
    Hung, Yi-Ping
    Jung, Lindsey
    Kuptsova-Clarkson, Nataliya
    Michelini, Flavia
    Puvvada, Soham D.
    Meric-Bernstam, Funda
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [32] Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study
    Oh, D-Y.
    Meric-Bernstam, F.
    Makker, V.
    Oaknin, A.
    Banerjee, S.
    Gonzalez Martin, A.
    Jung, K. H.
    Lugowska, I.
    Manso, L. M.
    Manzano, A.
    Melichar, B.
    Siena, S.
    Stroyakovskiy, D.
    Fielding, A.
    Ma, Y.
    Puvvada, S. D.
    Lee, J-Y.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1494 - S1495
  • [33] Spotlight on Trastuzumab Deruxtecan (DS-8201, T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer
    Azar, Ibrahim
    Alkassis, Samer
    Fukui, Jami
    Alsawah, Fares
    Fedak, Kalub
    Al Hallak, Mohammed Najeeb
    Sukari, Ammar
    Nagasaka, Misako
    [J]. LUNG CANCER-TARGETS AND THERAPY, 2021, 12 : 103 - 114
  • [34] Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study
    Meric-Bernstam, F.
    Makker, V.
    Oaknin, A.
    Oh, D. Y.
    Banerjee, S.
    Martin, A. Gonzalez
    Jung, K. H.
    Lugowska, I.
    Manso, L. M.
    Manzano, A.
    Melichar, B.
    Siena, S.
    Stroyakovskiy, D.
    Fielding, A.
    Ma, Y.
    Puvvada, S. D.
    Lee, J. Y.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1273 - S1274
  • [35] Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial (vol 42, 10.1200/JCO-24-01883, 2024)
    Goto, Koichi
    Goto, Yasushi
    Kubo, Toshio
    Ninomiya, Kiichiro
    Kim, Sang-We
    Planchard, David
    Ahn, Myung-Ju
    Smit, Egbert F.
    de Langen, Adrianus Johannes
    Perol, Maurice
    Pons-Tostivint, Elvire
    Novello, Silvia
    Hayashi, Hidetoshi
    Shimizu, Junichi
    Kim, Dong-Wan
    Kuo, Chih-Hsi
    Yang, James Chih-Hsin
    Pereira, Kaline
    Cheng, Fu-Chih
    Taguchi, Ayumi
    Cheng, Yingkai
    Feng, Wenqin
    Tsuchihashi, Zenta
    Janne, Pasi A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (30) : 3635 - 3635
  • [36] Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results.
    Meric-Bernstam, Funda
    Makker, Vicky
    Oaknin, Ana
    Oh, Do-Youn
    Banerjee, Susana N.
    Martin, Antonio Gonzalez
    Jung, Kyung Hae
    Lugowska, Iwona A.
    Manso, Luis
    Manzano, Aranzazu
    Melichar, Bohuslav
    Siena, Salvatore
    Stroyakovskiy, Daniil
    Anoka, Chiedozie
    Ma, Yan
    Puvvada, Soham D.
    Lee, Jung-Yun
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) : LBA3000 - LBA3000
  • [37] Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis
    Jerusalem, Guy
    Park, Yeon Hee
    Yamashita, Toshinari
    Hurvitz, Sara A.
    Modi, Shanu
    Andre, Fabrice
    Krop, Ian E.
    Farre, Xavier Gonzalez
    You, Benoit
    Saura, Cristina
    Kim, Sung-Bae
    Osborne, Cynthia R.
    Murthy, Rashmi K.
    Gianni, Lorenzo
    Takano, Toshimi
    Liu, Yali
    Cathcart, Jillian
    Lee, Caleb
    Perrin, Christophe
    [J]. CANCER DISCOVERY, 2022, 12 (12) : 2754 - 2762
  • [38] Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results.
    Meric-Bernstam, Funda
    Makker, Vicky
    Oaknin, Ana
    Oh, Do-Youn
    Banerjee, Susana N.
    Martin, Antonio Gonzalez
    Jung, Kyung Hae
    Lugowska, Iwona A.
    Manso, Luis
    Manzano, Aranzazu
    Melichar, Bohuslav
    Siena, Salvatore
    Stroyakovskiy, Daniil
    Anoka, Chiedozie
    Ma, Yan
    Puvvada, Soham D.
    Lee, Jung-Yun
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
  • [39] Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): Updated survival results from a phase II trial (DESTINY-Breast01)
    Saura Manich, C.
    Modi, S.
    Krop, I.
    Park, Y. H.
    Kim, S-B.
    Tamura, K.
    Andre, F.
    Iwata, H.
    Ito, Y.
    Tsurutani, J.
    Sohn, J.
    Lee, C.
    Liu, Y.
    Cathcart, J.
    Singh, J.
    Yamashita, T.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S485 - S486
  • [40] Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+advanced/metastatic breast cancer (mBC) with or without brain metastases (BM): DESTINYBreast-12 primary results
    Lin, N.
    Ciruelos, E. M.
    Jerusalem, G.
    Mueller, V.
    Niikura, N.
    Viale, G.
    Bartsch, R.
    Kurzeder, C.
    Connolly, R.
    Baron-Hay, S. E.
    Cortes, M. Gion
    Guarneri, V.
    Bianchini, G.
    Wildiers, H.
    Escriva-de-Romani, S.
    Prahladan, M.
    Bridge, H.
    Verma, S.
    Harbeck, N.
    [J]. ANNALS OF ONCOLOGY, 2024, 35 : 1211 - 1212
12345